Literature DB >> 25810135

Total chemical synthesis of human interferon alpha-2b via native chemical ligation.

Jing Li1,2, Clara Lehmann1,3, Xishan Chen1, Fabio Romerio1, Wuyuan Lu1.   

Abstract

Interferon-alpha (IFNα) is a cytokine that orchestrates innate and adaptive immune responses and potently inhibits proliferation of normal and tumor cells. These properties have warranted the use of IFNα in clinical practice for the treatment of several viral infections and malignancies. However, overexpression of IFNα leads to immunopathology observed in the context of chronic viral infections and autoimmune conditions. Thus, it is desirable to develop therapeutic approaches that aim at suppressing excessive IFNα production. To that end, artificial evolution of peptides from phage display libraries represents a strategy that seeks to disrupt the interaction between IFNα and its cell surface receptor and thus inhibit the ensuing biological effects. Mirror-image phage display that screens peptide libraries against the D-enantiomer is particularly attractive because it allows for identification of proteolysis-resistant D-peptide inhibitors. This approach, however, relies on the availability of chemically synthesized D-IFNα composed entirely of D-amino acids. Here, we describe the synthesis and biological properties of IFNα2b of 165 amino acid residues produced by native chemical ligation, which represents an important first step toward the discovery of D-peptide antagonists with potential therapeutic applications.
Copyright © 2015 European Peptide Society and John Wiley & Sons, Ltd.

Entities:  

Keywords:  interferon; native chemical ligation; peptide synthesis; synthetic protein

Mesh:

Substances:

Year:  2015        PMID: 25810135      PMCID: PMC4480187          DOI: 10.1002/psc.2760

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  46 in total

1.  In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences.

Authors:  M Schnölzer; P Alewood; A Jones; D Alewood; S B Kent
Journal:  Int J Pept Protein Res       Date:  1992 Sep-Oct

2.  Nomenclature of the human interferon proteins.

Authors:  G Allen; M O Diaz
Journal:  J Interferon Res       Date:  1994-08

3.  Identification of D-peptide ligands through mirror-image phage display.

Authors:  T N Schumacher; L M Mayr; D L Minor; M A Milhollen; M W Burgess; P S Kim
Journal:  Science       Date:  1996-03-29       Impact factor: 47.728

4.  The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution.

Authors:  W Klaus; B Gsell; A M Labhardt; B Wipf; H Senn
Journal:  J Mol Biol       Date:  1997-12-12       Impact factor: 5.469

5.  Human cytomegalovirus-associated immunosuppression is mediated through interferon-alpha.

Authors:  N Noraz; J L Lathey; S A Spector
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

6.  Interferon expression in the pancreases of patients with type I diabetes.

Authors:  X Huang; J Yuang; A Goddard; A Foulis; R F James; A Lernmark; R Pujol-Borrell; A Rabinovitch; N Somoza; T A Stewart
Journal:  Diabetes       Date:  1995-06       Impact factor: 9.461

7.  Induction of type I diabetes by interferon-alpha in transgenic mice.

Authors:  T A Stewart; B Hultgren; X Huang; S Pitts-Meek; J Hully; N J MacLachlan
Journal:  Science       Date:  1993-06-25       Impact factor: 47.728

8.  Synthesis of proteins by native chemical ligation.

Authors:  P E Dawson; T W Muir; I Clark-Lewis; S B Kent
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

9.  How to measure and predict the molar absorption coefficient of a protein.

Authors:  C N Pace; F Vajdos; L Fee; G Grimsley; T Gray
Journal:  Protein Sci       Date:  1995-11       Impact factor: 6.725

View more
  1 in total

Review 1.  Drug repurposing approach to fight COVID-19.

Authors:  Thakur Uttam Singh; Subhashree Parida; Madhu Cholenahalli Lingaraju; Manickam Kesavan; Dinesh Kumar; Raj Kumar Singh
Journal:  Pharmacol Rep       Date:  2020-09-05       Impact factor: 3.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.